Table 1

Patient demographics and tumour data

Patient No	Age	Sex	DM	HTN	Additional ocular disease	Eye	Tumour location	Size (mm)			TNM
Laser group	Age	Sex	DM	HTN	Additional ocular disease	Eye	Tumour location	Length	Width	Height	TNM
DM, diabetes mellitus; HTN, hypertension; ARMD, age related macular degeneration; BDR, background diabetic retinopathy; BRVO, branch retinal vein occlusion; E, equator; P, posterior; TNM, AJCC-UICC classification.
With retinopathy
1	63	F	–	Y	–	RE	530EP	12	9	2.8	T2N0M0
2	72	M	–	–	Glaucoma	LE	230EP	9	10	4.9	T2N0M0
3	84	M	–	–	–	LE	3EP	10	12	4.2	T2N0M0
4	52	M	–	–	–	RE	9EP	10.3	11	5.3	T2N0M0
5	56	F	–	–	–	RE	1EP	7	8	2.4	T1N0M0
6	81	F	–	–	–	RE	9EP	7	12	3.6	T2N0M0
7	67	M	–	Y	–	LE	230E	14	12.5	6.5	T2N0M0
8	86	M	–	–	–	LE	11E	10	12	6.2	T2N0M0
9	84	F	–	–	–	LE	430EP	6	8	4.4	T1N0M0
10	86	M	–	Y	ARMD	RE	1030EP	12	10	2.9	T2N0M0
11	34	F	–	–	–	RE	1PE	5	6	1.9	T1N0M0
12	72	M	Y	Y	BDR	LE	3EP	14	16	3.4	T2N0M0
13	86	F	–	Y	–	RE	1030EP	14	15	5.2	T2N0M0
14	72	M	Y	–	–	LE	230EP	10	10	3.4	T2N0M0
15	58	F	–	–	–	LE	1P	7	10	3.2	T2N0M0
16	81	M	Y	–	–	RE	230P	8	10	4.1	T2N0M0
17	55	F	–	Y	–	LE	230P	6	6	2.4	T1N0M0
18	68	F	–	–	–	LE	9EP	10	10	5.4	T2N0M0
19	86	F	Y	Y	ARMD	RE	730EP	12	13	5.4	T2N0M0
20	85	F	–	–	Glaucoma	LE	130EP	8	10	2.4	T2N0M0
21	86	F	–	–	–	RE	9EP	9	10	2.7	T2N0M0
22	71	F	–	–	–	RE	1030EP	8	9	2.4	T1N0M0
23	87	F	–	Y	–	LE	11PE	6	8	3.2	T1N0M0
24	59	F	–	–	–	LE	230EP	8	10	3	T2N0M0
25	62	F	–	Y	–	LE	9EP	10	10	3.5	T2N0M0
26	83	F	–	–	–	LE	430EP	9	9	2.9	T1N0M0
27	59	M	–	–	–	LE	4EP	10	12	2.7	T2N0M0
28	87	F	Y	Y	BDR	RE	430EP	10	10	2.7	T2N0M0
29	82	F	–	Y	Glaucoma	LE	3EP	6	6	3.5	T1N0M0
30	84	M	–	–	ARMD	LE	3EP	8	8	3.2	T1N0M0
31	82	M	–	–	ARMD	LE	430EP	9	12	3.4	T2N0M0
32	66	F	–	Y	–	RE	9EP	10	14	4.4	T2N0M0
33	70	M	–	–	–	RE	10EP	10	10	2.9	T2N0M0
34	55	M	–	–	–	RE	5P	7	8	5	T1N0M0
35	82	F	Y	Y	–	LE	230EP	12	10	3.4	T2N0M0
36	68	F	–	–	–	RE	6PE	14	12	5.8	T2N0M0
37	59	M	–	Y	–	RE	11P	8	8	2.4	T1N0M0
38	87	M	–	Y	–	RE	9EP	10	10	4.7	T2N0M0
39	73	F	Y	Y	–	RE	3EP	12	12	3.4	T2N0M0
40	54	M	–	–	–	RE	9EP	5	7	2.4	T1N0M0
41	66	M	–	–	ARMD	RE	4PE	9	9	3.7	T1N0M0
42	86	F	–	–	–	LE	9P	7	8	3.2	T1N0M0
43	79	M	–	–	Glaucoma	LE	130EP	9.9	10	2.9	T2N0M0
44	94	F	Y	Y	–	LE	3EP	10	10	2.4	T1N0M0
45	79	F	–	–	–	LE	430EP	10	10	2.7	T2N0M0
Prophylactic group
1	53	F	–	–	–	RE	1030EP	10	16	4	T2N0M0
2	66	M	–	–	–	LE	2EP	9	9	2.4	T1N0M0
3	78	F	–	–	–	LE	9EP	10.5	8	3	T2N0M0
4	31	M	–	–	–	LE	1P	9	10	3.6	T2N0M0
5	82	F	–	Y	–	RE	6E	12	13	3.2	T2N0M0
6	51	M	–	–	–	RE	12P	4	6	2.2	T1N0M0
7	59	F	–	–	–	LE	2EP	11	13	3.6	T2N0M0
8	83	F	–	–	Glaucoma	LE	2EP	9	11	2.7	T2N0M0
9	70	M	Y	–	–	LE	9E	12	16	4.9	T2N0M0
10	77	F	–	–	Glaucoma	RE	1030EP	6	7	2.5	T1N0M0
11	67	F	–	–	ARMD	RE	3PE	7	8	2	T1N0M0
12	68	M	–	–	–	LE	5EP	9	10	3.6	T2N0M0
13	47	M	–	–	Glaucoma/BRVO	RE	3PE	6	7	2.7	T1N0M0
14	86	F	–	Y	ARMD	RE	730EP	7	10	2.4	T1N0M0
15	87	M	–	Y	Glaucoma	RE	9P	8	8	2.8	T1N0M0
16	82	F	Y	Y	BDR	RE	1030EP	11	11	2.6	T2N0M0